{
  "denotations": [
    {
      "id": "T1",
      "obj": "Gene_or_protein",
      "span": {
        "begin": 36,
        "end": 47
      }
    },
    {
      "id": "T2",
      "obj": "Gene_or_protein",
      "span": {
        "begin": 50,
        "end": 54
      }
    },
    {
      "id": "T3",
      "obj": "Disease",
      "span": {
        "begin": 77,
        "end": 94
      }
    },
    {
      "id": "T4",
      "obj": "Chemical",
      "span": {
        "begin": 104,
        "end": 115
      }
    },
    {
      "id": "T5",
      "obj": "Chemical",
      "span": {
        "begin": 120,
        "end": 132
      }
    },
    {
      "id": "T6",
      "obj": "Gene_or_protein",
      "span": {
        "begin": 172,
        "end": 176
      }
    },
    {
      "id": "T7",
      "obj": "Gene_or_protein",
      "span": {
        "begin": 148,
        "end": 169
      }
    }
  ],
  "sourcedb": "PubMed",
  "sourceid": "21508389_3",
  "text": "Preclinical work has shown that the Kirsten ras ( KRAS ) oncogene sensitizes colorectal tumour cells to oxaliplatin and capecitabine in a wild-type tumour suppressor p53 ( TP53 ) - dependent manner ."
}
